Our data presented herein confirms these results in two preclinical breast cancers to bone metastases models and extends those to demonstrate that anti-TGFβ treatment increases mineralized matrix formation by osteoblasts as well as increases bone mass in preclinical bone metastasis models. Here, TGFB1 is linked to breast cancer.